| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4221471 | Clinical Imaging | 2015 | 6 Pages |
Abstract
We conducted a pooled analysis of clinical trials comparing intravenous Fenoldopam (FP) with Saline/Placebo/N-acetyl cysteine (NAC) for the prevention of contrast-induced nephropathy (CIN). Five studies were eligible. Quantitative analyses were done with Review Manager (RevMan version 5.2.). A total of 85 out of 353 patients in Fenoldopam group while 73 among 366 in the control group were affected due to CIN. The risk ratio for the development of CIN in the Fenoldopam group was 1.19 compared to the control group. This was not statistically significant. Fenoldopam is no better than Placebo/Saline or NAC in preventing CIN, but more studies are required.
Related Topics
Health Sciences
Medicine and Dentistry
Radiology and Imaging
Authors
Muhammad Naeem, Gregory E. McEnteggart, Timothy P. Murphy, Ethan Prince, Sun Ahn, Gregory Soares,